paid access

Vol 12, No 3 (2018)
Review articles
Published online: 2018-10-25
Get Citation

Opioids for the treatment of breathlessness. Are all opioids equally efficacious?

Zbigniew Żylicz
DOI: 10.5603/10.5603/PMPI.2018.0004
·
Palliat Med Pract 2018;12(3):151-155.

paid access

Vol 12, No 3 (2018)
Review articles
Published online: 2018-10-25

Abstract

Morfina jest uznanym lekiem do leczenia objawowego duszności w opiece paliatywnej, choć dowody na
jej działanie są ograniczone. Podana systemowo (doustnie, podskórnie i dożylnie) oraz drogą wziewną do
drzewa oskrzelowego, gdzie znajdują się receptory opioidowe, znacząco zmniejsza nasilenie duszności.
Efekt ten związany jest między innymi z obwodowym działaniem morfiny, która jest hydrofilnym opioidem.
Dowody na skuteczność w leczeniu objawowym duszności lipofilnych opioidów takich jak: fentanyl, są co
najmniej kontrowersyjne. Oprócz domniemanego działania przeciw duszności, fentanyl może spowodować
sztywność mięśni klatki piersiowej, co utrudnia oddychanie i zwiększa poczucie duszności.

Palliat Med Pract 2018; 12, 3: 151–155

Abstract

Morfina jest uznanym lekiem do leczenia objawowego duszności w opiece paliatywnej, choć dowody na
jej działanie są ograniczone. Podana systemowo (doustnie, podskórnie i dożylnie) oraz drogą wziewną do
drzewa oskrzelowego, gdzie znajdują się receptory opioidowe, znacząco zmniejsza nasilenie duszności.
Efekt ten związany jest między innymi z obwodowym działaniem morfiny, która jest hydrofilnym opioidem.
Dowody na skuteczność w leczeniu objawowym duszności lipofilnych opioidów takich jak: fentanyl, są co
najmniej kontrowersyjne. Oprócz domniemanego działania przeciw duszności, fentanyl może spowodować
sztywność mięśni klatki piersiowej, co utrudnia oddychanie i zwiększa poczucie duszności.

Palliat Med Pract 2018; 12, 3: 151–155

Get Citation

Keywords

breathlessness, morphine, fentanyl, pathophysiology of dyspnea

About this article
Title

Opioids for the treatment of breathlessness. Are all opioids equally efficacious?

Journal

Palliative Medicine in Practice

Issue

Vol 12, No 3 (2018)

Pages

151-155

Published online

2018-10-25

DOI

10.5603/10.5603/PMPI.2018.0004

Bibliographic record

Palliat Med Pract 2018;12(3):151-155.

Keywords

breathlessness
morphine
fentanyl
pathophysiology of dyspnea

Authors

Zbigniew Żylicz

References (41)
  1. Mercadante S, Aielli F, Adile C, et al. Epidemiology and Characteristics of Episodic Breathlessness in Advanced Cancer Patients: An Observational Study. J Pain Symptom Manage. 2016; 51(1): 17–24.
  2. Krajnik M, Schäfer M, Sobański P, et al. Local pulmonary opioid network in patients with lung cancer: a putative modulator of respiratory function. Pharmacol Rep. 2010; 62(1): 139–149.
  3. Pattinson KTS. Opioids and the control of respiration. Br J Anaesth. 2008; 100(6): 747–758.
  4. Barnes H, McDonald J, Smallwood N, et al. Opioids for the palliation of refractory breathlessness in adults with advanced disease and terminal illness. Cochrane Database Syst Rev. 2016; 3: CD011008.
  5. Zeppetella G. Nebulized morphine in the palliation of dyspnoea. Palliat Med. 1997; 11(4): 267–275.
  6. Farncombe M, Chater S. Clinical application of nebulized opioids for treatment of dyspnoea in patients with malignant disease. Support Care Cancer. 1994; 2(3): 184–187.
  7. Baydur A. Nebulized morphine: a convenient and safe alternative to dyspnea relief? Chest. 2004; 125(2): 363–365.
  8. Noseda A, Carpiaux JP, Markstein C, et al. Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. Eur Respir J. 1997; 10(5): 1079–1083.
  9. Krajnik M, Podolec Z, Siekierka M, et al. Morphine inhalation by cancer patients: a comparison of different nebulization techniques using pharmacokinetic, spirometric, and gasometric parameters. J Pain Symptom Manage. 2009; 38(5): 747–757.
  10. Janowiak P, Krajnik M, Podolec Z, et al. Air humidity may influence the aerosol distribution of normal saline administered by closed or vented nebulizers operated continuously or dosimetrically. J Aerosol Med Pulm Drug Deliv. 2009; 22(1): 29–34.
  11. Janowiak P, Krajnik M, Podolec Z, et al. Dosimetrically administered nebulized morphine for breathlessness in very severe chronic obstructive pulmonary disease: a randomized, controlled trial. BMC Pulm Med. 2017; 17(1): 186.
  12. Coda BA, Brown MC, Schaffer R, et al. Pharmacology of epidural fentanyl, alfentanil, and sufentanil in volunteers. Anesthesiology. 1994; 81(5): 1149–1161.
  13. Simon ST, Köskeroglu P, Gaertner J, et al. Fentanyl for the relief of refractory breathlessness: a systematic review. J Pain Symptom Manage. 2013; 46(6): 874–886.
  14. Pinna MÁ, Bruera E, Moralo MJ, et al. A randomized crossover clinical trial to evaluate the efficacy of oral transmucosal fentanyl citrate in the treatment of dyspnea on exertion in patients with advanced cancer. Am J Hosp Palliat Care. 2015; 32(3): 298–304.
  15. Hui D, Xu A, Frisbee-Hume S, et al. Effects of prophylactic subcutaneous fentanyl on exercise-induced breakthrough dyspnea in cancer patients: a preliminary double-blind, randomized, controlled trial. J Pain Symptom Manage. 2014; 47(2): 209–217.
  16. Hui D, Kilgore K, Park M, et al. Impact of Prophylactic Fentanyl Pectin Nasal Spray on Exercise-Induced Episodic Dyspnea in Cancer Patients: A Double-Blind, Randomized Controlled Trial. J Pain Symptom Manage. 2016; 52(4): 459–468.e1.
  17. Sitte T, Bausewein C. Intranasal fentanyl for episodic breathlessness. J Pain Symptom Manage. 2008; 36(6): e3–e6.
  18. Hui D, Kilgore K, Frisbee-Hume S, et al. Effect of Prophylactic Fentanyl Buccal Tablet on Episodic Exertional Dyspnea: A Pilot Double-Blind Randomized Controlled Trial. J Pain Symptom Manage. 2017; 54(6): 798–805.
  19. Simon ST, Kloke M, Alt-Epping B, et al. EffenDys-Fentanyl Buccal Tablet for the Relief of Episodic Breathlessness in Patients With Advanced Cancer: A Multicenter, Open-Label, Randomized, Morphine-Controlled, Crossover, Phase II Trial. J Pain Symptom Manage. 2016; 52(5): 617–625.
  20. Neidhart P, Burgener MC, Schwieger I, et al. Chest wall rigidity during fentanyl- and midazolam-fentanyl induction: ventilatory and haemodynamic effects. Acta Anaesthesiol Scand. 1989; 33(1): 1–5.
  21. Smith NT, Benthuysen JL, Bickford RG, et al. Seizures during opioid anesthetic induction--are they opioid-induced rigidity? Anesthesiology. 1989; 71(6): 852–862.
  22. Lynch RE, Hack RA. Methadone-induced rigid-chest syndrome after substantial overdose. Pediatrics. 2010; 126(1): e232–e234.
  23. Ellenbroek B, Schwarz M, Sontag KH, et al. Muscular rigidity and delineation of a dopamine-specific neostriatal subregion: tonic EMG activity in rats. Brain Res. 1985; 345(1): 132–140.
  24. Christian CM, Waller JL, Moldenhauer CC. Postoperative rigidity following fentanyl anesthesia. Anesthesiology. 1983; 58(3): 275–277.
  25. Ackerman WE, Phero JC, Theodore GT. Ineffective ventilation during conscious sedation due to chest wall rigidity after intravenous midazolam and fentanyl. Anesth Prog. 1990; 37(1): 46–48.
  26. Fahnenstich H, Steffan J, Kau N, et al. Fentanyl-induced chest wall rigidity and laryngospasm in preterm and term infants. Crit Care Med. 2000; 28(3): 836–839.
  27. Çoruh B, Tonelli MR, Park DR. Fentanyl-induced chest wall rigidity. Chest. 2013; 143(4): 1145–1146.
  28. Phua CK, Wee A, Lim A, et al. Fentanyl-induced chest wall rigidity syndrome in a routine bronchoscopy. Respir Med Case Rep. 2017; 20: 205–207.
  29. Dewhirst E, Naguib A, Tobias JD. Chest wall rigidity in two infants after low-dose fentanyl administration. Pediatr Emerg Care. 2012; 28(5): 465–468.
  30. Eventov-Friedman S, Rozin I, Shinwell ES. Case of chest-wall rigidity in a preterm infant caused by prenatal fentanyl administration. J Perinatol. 2010; 30(2): 149–150.
  31. MacGregor DA, Bauman LA. Chest wall rigidity during infusion of fentanyl in a two-month-old infant after heart surgery. J Clin Anesth. 1996; 8(3): 251–254.
  32. Zylicz Z, van Rijn-van der Plaat LL. Fentanyl may increase breathlessness in a patient with motor neuron disease. J Pain Symptom Manage. 2006; 32(3): 199–200.
  33. Vaughn RL, Bennett CR. Fentanyl chest wall rigidity syndrome--a case report. Anesth Prog. 1981; 28(2): 50–51.
  34. Viscomi CM, Bailey PL. Opioid-induced rigidity after intravenous fentanyl. Obstet Gynecol. 1997; 89(5 Pt 2): 822–824.
  35. Soares JH, Brosnan RJ, Smith A, et al. Rabbit model of chest wall rigidity induced by fentanyl and the effects of apomorphine. Respir Physiol Neurobiol. 2014; 202: 50–52.
  36. Oxberry SG, Torgerson DJ, Bland JM, et al. Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. Eur J Heart Fail. 2011; 13(9): 1006–1012.
  37. Oxberry SG, Bland JM, Clark AL, et al. Repeat dose opioids may be effective for breathlessness in chronic heart failure if given for long enough. J Palliat Med. 2013; 16(3): 250–255.
  38. Kawabata M, Kaneishi K. Continuous subcutaneous infusion of compound oxycodone for the relief of dyspnea in patients with terminally ill cancer: a retrospective study. Am J Hosp Palliat Care. 2013; 30(3): 305–311.
  39. Yamamoto Y, Watanabe H, Sakurai A, et al. Effect of continuous intravenous oxycodone infusion in opioid-naïve cancer patients with dyspnea. Jpn J Clin Oncol. 2018; 48(8): 748–752.
  40. Clemens K, Klaschik E. Effect of hydromorphone on ventilation in palliative care patients with dyspnea. Supportive Care in Cancer. 2007; 16(1): 93–99.
  41. Charles MA, Reymond L, Israel F. Relief of incident dyspnea in palliative cancer patients: a pilot, randomized, controlled trial comparing nebulized hydromorphone, systemic hydromorphone, and nebulized saline. J Pain Symptom Manage. 2008; 36(1): 29–38.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Medycyna Paliatywna w Praktyce dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl